Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.47 - $36.37
Previous CloseN/A
Volume49.09K
Average Volume (3M)330.76K
Market Cap
$724.56M
Enterprise Value$526.49M
Total Cash (Recent Filing)$235.69M
Total Debt (Recent Filing)$98.00K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 13, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding40,568,943
10 Day Avg. Volume422,337
30 Day Avg. Volume330,757
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$39.83Price Target Upside131.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe firm is expected to start the Ph3 ALPACCA trial in PACC, and first-mover advantage is a plus.
Drug EfficacyThe efficacy data shows a stable cORR of 68.2% in the 240mg dose group, indicating consistent performance.
Bears Say
Financial PerformanceArriVent reported a net loss wider than previously forecasted, with increased R&D and SG&A expenses.
Investor SentimentThe short interest is high at 22.5% of the float, indicating a significant amount of investors are betting against the stock.
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $36.37 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $724.56M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 47 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.712 by -$0.188.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.79.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 40,568,943 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.712. Following the earnings report the stock price went down -3.335%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.83 (131.97% Upside)
$39.83 (131.97% Upside)
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.70%
12-Months-Change
Fundamentals
Return on Equity
-50.13%
Trailing 12-Months
Asset Growth
-12.74%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$39.83
▲(131.97% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
1.53% Insiders
12.39% Mutual Funds
4.39% Other Institutional Investors
72.34% Public Companies and
Individual Investors